From Health Canada:
Health Canada is informing Canadians of new information submitted by the manufacturer of the antiviral drug Baraclude that suggests the drug may be linked to the development of a treatment-resistant strain of HIV in one patient with HIV.
For the Public
For Health Professionals
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment